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Background: Oral solution N-acetylcysteine (NAC) is an antidote for acetaminophen overdose, but its
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medications. Flavored effervescent NAC tablets dissolved in water might be a more palatable formulation
than oral solution NAC diluted with soft drink.
Objectives: To evaluate the relative bioavailability of these 2 formulations and assess subjective
preferences between them.
Methods: Thirty healthy adult volunteers (mean [SD] ¼ 35.2 [9.14] years) were enrolled in this open-
label, randomized, single-dose, crossover study, with a 7-day washout period. Volunteers were
randomized to receive 11 g effervescent test formulation or the reference product under fasting
conditions, after which 19 serial blood samples were collected over 48 hours. Total plasma NAC
concentrations were evaluated by LC-MS, and pharmacokinetic parameters were calculated. The
2 formulations were considered bioequivalent if the 90% CIs of log-transformed ratios of pharmacoki-
netic parameters were within the predetermined bioequivalence range (80%–125%) established by the US
Food and Drug Administration. Within 15 minutes of dosing, subjects were also asked to rank
formulation attributes on a 5-point hedonic scale, with mean group differences analyzed by Wilcoxon
signed rank test. Safety-proﬁle assessment included treatment-emergent adverse events, physical
examination, chemistry, and hematology parameters.
Results: The concentration-versus-time proﬁles were similar for the 2 formulations, with mean Cmax of
26.5 μg/mL for effervescent NAC tablets and 28.4 μg/mL for oral solution NAC. The 90% CIs for the
pharmacokinetic parameters met the criteria for concluding bioequivalence, and subjects preferred
effervescent NAC tablets in terms of taste (P ¼ 0.0247), ﬂavor (P ¼ 0.0082), texture (P ¼ 0.009), and
overall likeability (P ¼ 0.0012), but there was no difference for smell (P ¼ 0.0533). All treatment-
emergent adverse events were mild, with no differences between the treatment groups.
Conclusions: Data from this study of a single dose of 11 g oral NAC demonstrated that effervescent NAC
tablets and oral solution NAC met the regulatory criteria for bioequivalence in fasting healthy adult
subjects. Effervescent NAC tablets appear to be a more palatable alternative for treatment of
acetaminophen overdose. ClinicalTrials.gov identiﬁer: NCT02723669. (Curr Ther Res Clin Exp. 2016;
83C:1–7) © 2016 Elsevier HS Journals, Inc.
& 2016. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Inc. This is an open access article u
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acock).Introduction
In the United States, acetaminophen is the medicine that is
most commonly associated with overdose and the leading cause of
overdose-related hepatotoxicity leading to acute liver failure.1
Approximately half of overdose-related deaths are due to products
containing acetaminophen in combination with other drugs.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Control Centers,2 overuse of either acetaminophen alone or in
combinations with other drugs accounted for the highest percent-
age of fatalities (16.9%) associated with single-substance exposures
alone (10.70%) and in combinations (6.23%). In a 2011 epidemiol-
ogy study,3 acetaminophen-associated overdoses were responsible
for an average of 78,414 annual emergency department visits and
an average of 33,520 annual hospitalizations.
Oral solution N-acetylcysteine (NAC) was approved by the Food
and Drug Administration (FDA) for treatment of acetaminophen
overdose in 1978. Single large doses or repeated subtherapeutic
doses of acetaminophen can deplete hepatic glutathione, which
detoxiﬁes N-acetyl-p-benzoquinone imine, a metabolite of acet-
aminophen that is extremely toxic to the liver. NAC prevents
hepatic injury primarily by restoring hepatic glutathione.1 The
FDA-approved treatment protocol for use of oral NAC as an
acetaminophen-overdose antidote requires a loading dose fol-
lowed by 17 additional doses over 72 hours. Shortened courses
of oral NAC (r48 hours), guided by laboratory parameters for
patient-tailored discontinuation of treatment, have also been
studied and are sometimes used.4,5 Intravenous (IV) NAC was
approved by the FDA for treatment of acetaminophen overdose
in 2004. The FDA-approved treatment protocol for use of IV NAC
requires a loading dose followed by 2 additional doses over 21
hours. Both oral solution NAC and IV NAC are highly effective in
preventing hepatotoxicity from acetaminophen overdose, with
comparable efﬁcacy.6,7 In the United States, institutional prefer-
ence for either oral solution NAC or IV NAC for treatment of
acetaminophen overdose depends on such factors as manpower
and utilization costs associated with delivery of these different
formulations.7
Because of its sulfur moiety, NAC has a putrid rotten-egg smell
and taste, which can cause patients to experience nausea and
vomiting and become intolerant of therapy. For patients receiving
oral solution NAC, vomiting can be sufﬁcient to impede medication
delivery. Gastrointestinal adverse events occur not only with oral
NAC solution, which is commonly diluted with diet caffeine-free
soft drink to mask the smell and taste, but with IV NAC as well.
These symptoms are often treated with antiemetic agents. In a
retrospective, 503-patient multicenter comparison of the safety of
oral versus IV NAC for treatment of acetaminophen overdose, the
rate of nausea and vomiting was higher with oral NAC than with IV
NAC (23% vs 9%), but the same percentage of patients in each
group required antiemetic medication (25.5% vs 26.5%).8
Flavored effervescent tablets are a novel formulation of NAC
intended for oral treatment of acetaminophen overdose. When
effervescent NAC tablets are dissolved in water, the ﬂavored taste
and smell of the solution might be preferred to the combination of
oral solution NAC diluted with diet caffeine-free soft drink. Our
purpose was to compare the pharmacokinetic (PK) parameters and
relative bioavailability of effervescent NAC tablets and oral solutionRandomization
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Figure 1. Study design of the open-label, randomized-sequence, single-dose, cro
N-acetylcysteine (NAC) tablets and oral solution NAC in fasting healthy adult subjects.NAC given as a single 11-g dose under fasting conditions to healthy
adult subjects. This study was conducted in accordance with FDA
regulatory criteria for assuming bioequivalence of orally adminis-
tered drugs.9 A secondary objective of this study was to assess
subject preferences for attributes of effervescent NAC tablets
compared with those of oral solution NAC.Materials and Methods
Study design and subjects
To evaluate the relative bioavailability of effervescent NAC
tablets versus oral solution NAC, we performed an open-label
crossover study in 30 male and female subjects with a body mass
index o 30 and who were between the ages of 18 and 50 years.
Conducted at a single research center, which recruited and paid
volunteers to participate, the study consisted of a screening period,
2 crossover dosing periods (Period 1 and Period 2), with the actual
dosing separated by a 7-day washout period, and a follow-up
telephone call (Figure 1). Because of the obvious differences
between the effervescent formulation and the standard solution,
subjects and investigators were aware of treatment assignment.
The study was approved by the local institutional review board
and was conducted in accordance with the principles in the World
Medical Association Declaration of Helsinki. The ClinicalTrials.gov
registration number for this trial was NCT02723669.
After providing informed consent, subjects underwent baseline
testing, which included medical history, clinical examination,
laboratory tests, and 12-lead ECG within the 30 days before
starting the study. Inclusion required being a nonsmoker and a
negative ß-human chorionic gonadotropin test in reproduction-
capable women. Subjects were not allowed prescription or over-
the-counter drugs (including vitamins and natural supplements)
throughout the study duration.
On study Day 0, a basic metabolic proﬁle with liver-function
tests, complete blood count, and urinalysis were administered.
Subjects were then provided a standard meal and fasted overnight
for at least 10 hours. Subjects then underwent randomization
using a balanced block randomization schedule, generated before
the start of dosing, to ensure alternating NAC formulations for the
crossover investigation.
Subjects received the ﬁrst assigned formulation on Day 1
(Period 1), with samples for PK analysis collected predose and at
scheduled postdose time points through 48 hours. Subjects com-
pleted a formulation-attribute survey within 15 minutes after
completing dosing activities. Period 1 ended when subjects were
discharged on Day 3. They then were readmitted on Day 7 for the
beginning of Period 2. The crossover washout was 7 days—from
the administration of the ﬁrst dose on Day 1 to the administration
of the assigned crossover NAC formulation on Day 8, again underOUT
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ssover, relative bioavailability and attribute-preference study of effervescent
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PK and safety-proﬁle assessments and completed the same
formulation-attribute survey as during Period 1. Patients were
discharged on Day 10 after a ﬁnal evaluation.
Study drugs and study drug administration
The effervescent tablet formulation of NAC (Cetylev, Arbor
Pharmaceuticals, Atlanta, Georgia) was available in strengths of
500 mg and 2.5 g. Each tablet was white, round, ﬂat, and debossed
to signify the dose strength. When a tablet was dissolved in water,
the mixture had a lemon-mint ﬂavor. The tablets were packaged in
silver 2-count peelable foil blister packs, which were not opened
until the time of use. The reference oral solution NAC, manufac-
tured by Gland Pharma Ltd for APP Pharmaceuticals, LLC (Schaum-
burg, Illinois), had a dose strength of 20% (200 mg/mL).
A dose of 11 g NAC was selected for evaluation because it
approximated the therapeutic loading dose for an adult weighing
70 to 79 kg who was receiving treatment for acetaminophen
overdose (a loading dose of 140 mg/kg).10 The doses of efferves-
cent NAC tablets, dissolved in water, and of oral solution NAC,
diluted with soft drink, were used within 10 minutes of prepara-
tion and were administered to subjects while in the sitting
position.
Subjects received 11 g (four 2.5-g and two 0.5-g tablets)
effervescent NAC dissolved in 300 mL room-temperature bottled
water. After the complete dose was consumed, the dosing glass
was rinsed with 100 mL water that was swallowed. Subjects
received 55 mL 20% NAC solution (a total of 11 g NAC) diluted
with 165 mL diet caffeine-free lemon-lime soft drink (a volume of
220 mL) (Shasta Diet Lemon Lime Twist, Shasta Food Service,
Gainesville, Georgia). The prescribing information for generic oral
solution NAC speciﬁes that dilution should occur with diet cola or
with other diet soft drinks. A soft drink with a lemon-lime ﬂavor
was chosen for dilution because that ﬂavor seemed most similar to
the lemon-mint ﬂavor of effervescent NAC tablets. After the dose
of oral solution NAC was consumed, 80 mL room-temperature
water was poured into the same container and swallowed, for a
total volume of 300 mL. After the complete dose was consumed,
the dosing glass was rinsed with 100 mL water that was swal-
lowed. A visual mouth check was performed after drug admin-
istration to conﬁrm that each study subject had completely
swallowed the full dose. Subjects remained in a sitting posture
for the ﬁrst 4 hours after dose administration in each period,
except in cases of study or procedural requirements. All subjects
maintained a fasting state for at least 4 hours after dosing in each
period.
PK evaluation
Blood samples were collected from all subjects on Day 1 and
Day 8 for the measurement of NAC. For PK analysis, samples were
collected predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8,
10, 12, 24, 36, and 48 hours postdose in each period. The predose
sample was obtained within 60 minutes before dosing. An indwel-
ling venous catheter was placed for PK blood sample collection
through 12 hours, and direct venipuncture or an indwelling
catheter could be used for PK sample collection at 24, 36, and 48
hours. The start time of each PK sampling was recorded
electronically.
Plasma samples of all subjects were assayed for total NAC using
LC-MS/MS carried out at AIT Bioscience, LLC (Indianapolis, Indi-
ana). The bioanalytical method was developed in compliance with
AIT Bioscience standard operating procedures and validated with
procedures and documentation consistent with FDA and European
Medicines Agency requirements11,12 and with a 2007 industryconsensus white paper.13 Covering the measurement range of 0.05
to 50.0 μg/mL NAC, with N-acetyl-L-cysteine-D3 used as the
respective internal standard, the bioanalytical method was based
on a simultaneous reduction/thioether formation reaction to form
a stable and easily detected derivative, followed by protein
precipitation extraction and LC-MS/MS instrumental analysis. No
samples were reassayed because of aberrant PK values.
Concentration-time data for total NAC for individual subjects
were analyzed by noncompartmental methods using actual
elapsed blood draw times in WinNonlin (version 5.3) (Pharsight,
Cary, North Carolina). Plasma concentration–time data were sum-
marized by descriptive statistics at each scheduled time point.
Individual and mean concentration–time proﬁles were provided
for each treatment arm. Plots were presented for the mean (SD)
plasma concentration versus time on linear and semilogarithmic
scales. Descriptive statistics for the PK parameters were tabulated
by treatment.
The natural log transformed values for the PK parameters Cmax,
AUC0–last, and AUC0–1 were analyzed for statistical differences
between effervescent NAC tablets and oral solution NAC using a
linear mixed model with ﬁxed effects for sequence, treatment, and
period, and a random effect for subject nested in sequence. The
90% CIs were calculated for the ratio of test and reference products
using the natural log transformed values for the PK parameters
Cmax, AUC0–last, and AUC0–1. Tmax was analyzed using nonpara-
metric analysis for the same comparisons shown for 90% CIs.
Bioequivalence could be concluded if the 90% CIs of the estimated
mean ratios (expressed as a percentage) fell entirely within the
80% to 125% limits established by the FDA.9
Analysis populations
The safety population, used for all safety-proﬁle and preference
survey analyses, included all subjects who received any amount of
study drug. The safety proﬁle was assessed by evaluation of
adverse events, hematology, chemistry, and urinalysis laboratory
test results, vital signs, physical examination, and ECG ﬁndings.
Subjects were monitored throughout the study and asked about
how they felt at the time of each clinical examination and during
the recording of vital signs. The PK population, used for all PK
analyses, included all subjects who completed both treatment
periods and had sufﬁcient quantiﬁable plasma concentration data
to provide Cmax and AUC data. No subjects were excluded due to
aberrant PK values.
Formulation attribute assessment
Within 15 minutes after completing dosing activities in each
period, subjects were asked to evaluate the taste, smell, ﬂavor,
texture, and overall likeability for the assigned product using the
adapted British Nutrition Foundation Sensory Evaluation 5-point
hedonic scale, ranging from “dislike very much” to “like very
much.”14 Deﬁnitions of the evaluated attributes were not provided
to subjects before the study began. Subjects were instructed not to
discuss their opinions with others and were housed in private
rooms to minimize communication and inﬂuence from other
subjects. The health care providers were also instructed not to
discuss the formulation attributes with the subjects or with one
another.
Statistical analysis
Continuous variables were summarized with means (SD),
medians, and ranges. Categorical variables were summarized by
counts and by percentage of subjects in corresponding categories.
For the formulation-attribute survey, the Wilcoxon signed rank
Table I
Total N-acetylcysteine (NAC) pharmacokinetic parameters and reference bioavail-
ability of effervescent NAC tablets versus oral solution NAC.*
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difference in scale between the 2 treatment groups was equal
to zero.Parameter Effervescent NAC
tablets (n ¼ 29)
Reference oral solution
NAC (n ¼ 29)
Tlag (h)† 0.00 (0.00) 0.00 (0.00)
Cmax (μg/mL) 26.5 (7.58) 28.4 (7.86)
Tmax (h) 2.12 (0.677) 1.89 (0.80)
AUC0–last (h  μg/mL) 179 (52.3) 195 (62.6)
AUC0–1 (h  μg/mL) 186 (54.3) 202 (64.4)
AUCextrap (%)‡ 3.61 (0.939) 3.43 (0.842)
λz (L/h)§ 0.0404 (0.0112) 0.0407 (0.00703)
t1/2 (h) 18.1 (3.96) 17.5 (2.98)
CL/F (L/h)|| 65.1 (22.8) 59.3 (16.3)
Vz/F (L)¶ 1720 (731) 1510 (503)
Fr (%)# 94.0 (18.5)
n Values are presented as mean (SD). One subject discontinued during Period
2 without receiving effervescent NAC tablets and is not included in these data.
† Lag time (time before ﬁrst quantiﬁable concentration).
‡ AUC extrapolated from the time of last non-zero concentration (Tlast) to
inﬁnity.
§ Apparent ﬁrst-order terminal rate constant.
|| Apparent clearance, calculated as dose/AUC1.
¶ Apparent volume of distribution, calculated as dose/(AUC1  λz).
# Bioavailability relative to reference product calculated as the test/reference
ratio of AUC1 values  100.Results
A total of 30 healthy subjects (25 male and 5 female) were
enrolled (age ¼ 35.2 [9.14] years; body mass index ¼ 26.97 [1.99]).
One adult male subject was withdrawn from the study before the
dosing of Period 2 because of a nonserious, mild, and unrelated
treatment-emergent adverse event (TEAE) more than 24 hours
after receipt of oral solution NAC in Period 1. Consequently, 29
subjects completed both treatment periods and were included in
the PK population. All subjects received some study drug and were
thus included in the safety population, with 29 of the subjects
receiving effervescent NAC tablets and all 30 subjects receiving
oral solution NAC.
Concentrations of NAC
All predose concentrations were less than the limit of quanti-
tation (o0.050 mg/mL). The mean Cmax of NAC in subjects
receiving effervescent NAC tablets was 26.5 mg/mL, and the mean
Cmax of NAC in subjects receiving oral solution NAC was 28.4 mg/
mL. The concentration-versus-time proﬁles were similar for the
2 products. Total NAC concentration-versus-time proﬁles, showing
mean (SD) concentration values for the PK population, are pre-
sented in linear scale in Figure 2.
PK and bioequivalence analysis
PK parameters were generated from the plasma total NAC
concentrations and actual elapsed blood sampling times. Summary
statistics for the total NAC parameters are provided in Table I. The
mean (SD) relative bioavailability (calculated with AUC0–1) of
effervescent NAC tablets versus oral solution NAC was 94.0%
(18.5%).
Results for the analysis of bioequivalence of effervescent NAC
tablets and reference oral solution NAC with respect to Cmax,
AUC0–last, and AUC0–1 are provided in Table II. Because the 90%Effervescent
NAC tablets
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Figure 2. Mean (SD) concentrations of total N-acetylcysteine (NAC) in a linear scale for efCIs for the effervescent NAC tablets and the reference oral solution
NAC were within the accepted range for bioequivalence (80%–
125%),9 the 2 products were bioequivalent with respect to Cmax,
AUC0–last, and AUC0–1.TEAEs
A total of 52 TEAEs were reported during the study. Fourteen of
29 subjects (48.3%) experienced 23 TEAEs while receiving effer-
vescent NAC tablets; 15 of 30 subjects (50.0%) experienced 29
TEAEs while receiving the reference product (Table III). The most
common TEAEs reported by more than 1 subject, regardless of the
product, were diarrhea, ﬂatulence, nausea, dysgeusia, upper
abdominal pain, headache, abdominal discomfort, vomiting, and
dizziness. After administration of effervescent NAC tablets and oral
solution NAC, a similar number of subjects reported TEAEs ofReference oral
solution NAC
ost-dose
24 30 36 42 48
fervescent NAC and oral solution NAC in the pharmacokinetics population (N ¼ 29).
Table II
Bioequivalence of effervescent N-acetylcysteine (NAC) tablets and oral solution NAC
for prespeciﬁed pharmacokinetic parameters.
Parameter Effervescent
NAC tablets
(LSM)
Reference
oral solution
NAC (LSM)
Ratio (%
reference
product)
90% CI ANOVA
%CV
AUC0–1
(h  μg/mL)
177.31 192.15 92.28 86.39–98.56 14.81
AUC0–last
(h  μg/mL)
170.90 185.54 92.11 86.18–98.44 14.94
Cmax (μg/mL) 25.44 27.46 92.64 86.84–98.84 14.54
LSM ¼ least squares mean.
Table IV
Subject preference survey results for formulation attributes.*
Attribute Effervescent NAC
tablets (n ¼ 29)
Reference oral solution
NAC (n ¼ 30)
P value†
Taste 0.0247
Like very much 1 (3.4) 0
Like 7 (24.1) 0
Neither like nor dislike 5 (17.2) 4 (13.3)
Dislike 7 (24.1) 20 (66.7)
Dislike very much 9 (31.0) 6 (20.0)
Smell 0.0533
Like very much 1 (3.4) 0
Like 5 (17.2) 1 (3.3)
Neither like nor dislike 5 (17.2) 7 (23.3)
Dislike 12 (41.4) 14 (46.7)
Dislike very much 6 (20.7) 8 (26.7)
Flavor 0.0082
Like very much 0 0
Like 8 (27.61) 0
Neither like nor dislike 6 (20.7) 4 (13.3)
Dislike 7 (24.1) 19 (63.3)
Dislike very much 8 (27.6) 7 (23.3)
Texture 0.0090
Like very much 1 (3.4) 0
Like 7 (24.1) 4 (13.3)
Neither like nor dislike 18 (62.1) 15 (50.0)
Dislike 2 (6.9) 8 (26.7)
Dislike very much 1 (3.4) 3 (10.0)
Overall likeability 0.0012
Like very much 2 (6.9) 0
Like 7 (24.1) 0
Neither like nor dislike 9 (31.0) 6 (20.0)
Dislike 5 (17.2) 18 (60.0)
Dislike very much 6 (20.7) 6 (20.0)
NAC ¼ N-acetylcysteine.
n Values are presented as number (%). One subject discontinued during Period
S.C. Greene et al. / Current Therapeutic Research 83C (2016) 1–7 5nausea (4 [13.8%] and 3 [10.0%], respectively) or vomiting (1 [3.4%]
and 1 [3.3%], respectively).
All TEAEs were considered to be mild in intensity. Of the
subjects who experienced TEAEs, events considered related to
study drug were reported for 13 of 14 subjects receiving efferves-
cent NAC tablets and 14 of 15 subjects receiving oral solution NAC.
All TEAEs reported by more than 1 subject overall were considered
related to study drug. There were no apparent differences in time
to onset or duration for the TEAEs of diarrhea, ﬂatulence, and
nausea after administration of effervescent NAC tablets or refer-
ence product. For the other TEAEs, the numbers of subjects
experiencing events was too small (1–3 subjects per treatment
group), to allow a meaningful comparison. No deaths or other
serious adverse events were reported during this study.
One 38-year-old male subject did not complete both treatment
periods of the study. He experienced a nonserious, mild, and
unrelated TEAE of syncope and seizure-like activity (ie, convul-
sion) without a postictal period before dosing during Period 2 and
was discontinued from the study. The event occurred more thanTable III
Frequency of subjects experiencing treatment-emergent adverse events in the
safety population.*
Incident Effervescent NAC
tablets (n ¼ 29)
Reference oral
solution NAC (n ¼ 30)
Subjects reporting at least
1 TEAE†
14 (48.3) 15 (50.0)
Subjects reporting at least
1 nausea or vomiting TEAE
4 (13.8) 3 (10.0)
Subjects reporting at least
1 serious TEAE
0 0
Gastrointestinal disorders 11 (37.9) 9 (30.0)
Diarrhea 6 (20.7) 6 (20.0)
Flatulence 2 (6.9) 5 (16.7)
Nausea 4 (13.8) 3 (10.0)
Abdominal pain upper 3 (10.3) 1 (3.3)
Abdominal discomfort 1 (3.4) 1 (3.3)
Vomiting 1 (3.4) 1 (3.3)
Nervous system disorders 4 (13.8) 7 (23.3)
Dysgeusia 3 (10.3) 3 (10.0)
Dizziness 1 (3.4) 1 (3.3)
Headache 0 2 (6.7)
Convulsion 0 1 (3.3)
Syncope 0 1 (3.3)
Closest relationship to study
drug
Related‡ 13 (44.8) 14 (46.7)
Not related§ 1 (3.4) 1 (3.3)
NAC ¼ N-acetylcysteine; TEAE ¼ treatment-emergent adverse event.
n Values are presented as number (%).
† Subjects reporting more than 1 adverse event are counted only once using the
closest relationship to study drug.
‡ Includes all events reported as “possible,” “probable,” “deﬁnitely,” or missing
relationship to study drug.
§ Includes all events reported as “unlikely” or “unrelated” relationship to
study drug.
2 without receiving the Period 2 treatment (effervescent NAC tablets).
† Wilcoxon signed rank test.24 hours after the subject received the reference oral solution NAC
during Period 1, with the total event lasting 2 to 4 minutes.
Because there were no meaningful differences between effer-
vescent NAC tablets and oral solution NAC in terms of TEAEs, vital
signs, ECG readings, or laboratory values, the safety proﬁle for
effervescent NAC tablets was found to be comparable to that for
oral solution NAC.
Subject preference
The results of the preference survey indicated that subjects pre-
ferred effervescent NAC tablets over reference oral solution NAC
for all 5 surveyed formulation attributes (ie, taste, smell, ﬂavor,
texture, and overall likeability). For 4 of these 5 attributes (ie, taste,
ﬂavor, texture, and overall likeability), the preference for efferves-
cent NAC tablets was statistically signiﬁcant (P values of 0.0247,
0.0082, 0.0090, and 0.0012, respectively, by Wilcoxon signed rank
test) (Table IV). For the attribute of smell, effervescent NAC tablets
were numerically preferred over the reference product, but this
preference did not reach statistical signiﬁcance (P ¼ 0.0533 by
Wilcoxon signed rank test). More subjects “liked,” “liked very
much,” or ranked effervescent NAC tablets as neutral for taste
(Figure 3).
Regarding overall likeability, during the ﬁrst dosing period,
when all subjects were naive to both treatments, preference was
higher for effervescent NAC tablets. Of 15 subjects receiving
effervescent NAC tablets on the ﬁrst day, 47% marked “liked” or
“liked very much,” whereas none of the 15 subjects who received
the reference product marked “liked” or “liked very much” on the
survey. Approximately 3 times as many subjects rated effervescent
NAC tablets (compared with the reference product) as positive
44.7
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Figure 3. Percent of subjects ranking formulation attributes of effervescent N-acetylcysteine (NAC) tablets and oral solution NAC as “like very much,” “like,” or “neither like
nor dislike.”
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(73.3% vs 20%). During the second dosing period, although the
products were generally assessed as less “liked” compared with
the ﬁrst week, fewer subjects disliked (“disliked” or “disliked very
much”) effervescent NAC tablets compared with the reference
product (50.0% vs 80.0%).Discussion
In this single-center, open-label, randomized, single-dose,
crossover, relative-bioavailability study, the bioavailability of effer-
vescent NAC tablets was not different from that of the reference
product, oral solution NAC, in healthy adult subjects under fasting
conditions. The single 11-g doses of either formulation approxi-
mated the loading dose of oral NAC treatment for acetaminophen
overdose. For the 2 formulations, the 90% CIs for the prespeciﬁed
PK parameters of Cmax, AUC0–last, and AUC0–1 were within the
accepted bioequivalence interval of 80% to 125%, meeting the
regulatory criteria for assuming bioequivalence in fasting healthy
adult subjects.9 Both products were well tolerated, with no serious
adverse events during the study, and with similar numbers of
patients in each group experiencing at least 1 TEAE: 14 of 29
subjects (48.3%) after receiving effervescent NAC tablets and 15 of
30 subjects (50.0%) after receiving oral solution NAC. There were
no meaningful treatment-related differences between effervescent
NAC tablets and oral solution NAC during the study.
Subjects preferred effervescent NAC tablets (with lemon-mint
ﬂavor) dissolved in water to oral solution NAC diluted in diet
caffeine-free lemon-lime soft drink in terms of taste, ﬂavor,
texture, and overall likability. For the formulation attribute of
overall likeability, 62.0% of subjects ranked effervescent NAC
tablets “like very much,” “like,” or “neither like nor dislike,”
whereas only 20.0% of patients ranked oral solution NAC “like
very much,” “like,” or “neither like nor dislike.”
The absorption time of NAC is critical because of the narrow 8-
to 10-hour window in which the drug is most effective in
preventing acetaminophen-induced hepatotoxicity. Thus an
advantage of the availability of a more palatable oral formulation
of NAC for treatment of acetaminophen overdose—a formulation
that better mitigates the putrid smell and taste of NAC—might be
that NAC administration would be delayed for fewer patients.
Unlike IV NAC, orally administered NAC undergoes an extensiveﬁrst-pass metabolism so that the entire dose passes through the
liver, the potential site of damage, with resulting high NAC
concentrations.15
The availability of a more palatable oral NAC formulation might
also reduce the number of patients requiring antiemetic agents or
several doses of such agents to tolerate treatment. In a small, retro-
spective study comparing antiemetic use between patients receiving
oral solution NAC (n ¼ 20) and IV NAC (n ¼ 17) for treatment of
acetaminophen overdose, Miller et al16 found that subjects receiving
oral solution NAC required 2.8 (0.7) doses of antiemetic medication,
whereas subjects receiving IV NAC required 1.1 (0.2) doses of an
antiemetic medication (P ¼ 0.04). Altogether, 75.0% of patients treated
with oral solution NAC received antiemetic therapy in contrast to
58.8% of the patients treated with IV NAC (P ¼ 0.48).
Another advantage of effervescent NAC tablets might be pre-
paration convenience for practitioners and patients outside the
emergency department in selected cases. For example, after
administration of the loading dose of NAC in the emergency
department for acetaminophen overdose, if the patient is well
and clearly not intending self-harm, the patient could be dis-
charged from the emergency department with additional doses of
oral NAC (70 mg/kg) to be taken every 4 hours, with scheduled
returns to an outpatient clinic for repeat measurements of alanine
aminotransferase activity.17
There were limitations to the present study. Data were obtained
from a small number of healthy adult subjects, under fasting
conditions, after administration of a single 11-g dose of NAC. The
PK proﬁles of effervescent NAC tablets and oral solution NAC might
be different in other populations, although that is unlikely because
both products were administered as oral solutions. Because this
was a single-dose PK study, meaningful safety-proﬁle conclusions
cannot be drawn from small differences between the treatments.
The lemon-mint ﬂavor of the effervescent NAC tablets dissolved in
water was not exactly the same as the lemon-lime ﬂavor of the
diet caffeine-free soft drink in which oral solution NAC was
diluted, a difference that could have affected the preference of
formulation attributes. Because the formulation attributes were
not deﬁned for the subjects before the study began, their meaning
was subjectively interpreted, and that could have affected prefer-
ence choices. Finally, the study was open label, with subjects and
investigators both aware of formulation assignment, which might
have affected the evaluation of tolerability and inﬂuenced subject
preference of formulation attributes.
S.C. Greene et al. / Current Therapeutic Research 83C (2016) 1–7 7Conclusions
The data from this study of a single 11-g dose of oral NAC
demonstrated that effervescent NAC tablets and oral solution NAC
met the regulatory criteria for assuming bioequivalence in fasting
healthy adult subjects. Both formulations were well tolerated, but
subjects preferred the formulation attributes of effervescent NAC
tablets to those of oral solution NAC.Acknowledgments
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